Effect of Risk Mitigation Guidance for opioid and stimulant dispensations on mortality and acute care visits during dual public health emergencies: retrospective cohort studyAmanda Slaunwhite, Bohdan Nosyk, Jeong Eun Min et al.|BMJ|2024Cited by 95
Buprenorphine/Naloxone vs Methadone for the Treatment of Opioid Use DisorderBohdan Nosyk, M. Eugenia Socías, Thomas M. Loughin et al.|JAMA|2024Cited by 60
Opioid Coprescription Through Risk Mitigation Guidance and Opioid Agonist Treatment ReceiptJeong Eun Min, Bohdan Nosyk, Brenda Carolina Guerra‐Alejos et al.|JAMA Network Open|2024Cited by 14
Comparative effectiveness of urine drug screening strategies alongside opioid agonist treatment in British Columbia, Canada: a population-based observational study protocolBrenda Carolina Guerra‐Alejos, Bohdan Nosyk, Megan Kurz et al.|BMJ Open|2023Cited by 12
Comparative Analysis of Instrumental Variables on the Assignment of Buprenorphine/Naloxone or Methadone for the Treatment of Opioid Use DisorderFahmida Homayra, Bohdan Nosyk, Benjamin Enns et al.|Epidemiology|2023Cited by 9